UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology

13Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.

Cite

CITATION STYLE

APA

Price, M. J., Nguyen, A. D., Byemerwa, J. K., Flowers, J., Baëta, C. D., & Goodwin, C. R. (2023). UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology. Oncotarget. Impact Journals LLC. https://doi.org/10.18632/oncotarget.28514

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free